Programme et résumés de la 9e réunion du réseau national

Pro
g
s
22 - 23
Centre c
o
A
gence nationale de recherches sur le
g
ramme
et
et
s
umés
janvier 2009
o
ngrès UICP, Paris
sida et les hépatites virales
1
2
SOMMAIRE
RECEPTORCOMPLEMENTATIONANDTARGETEDMUTAGENESISREVEALSRBIASANESSENTIALHCVCELL
ENTRYFACTORANDFUNCTIONALLYIMPLYITSINTRA‐ANDEXTRACELLULARDOMAINS
(M.DREUX)..................................................................................................................................................10
SCAVENGERRECEPTORCLASSBTYPEIANDSERUMDERIVEDHEPATITISCVIRUSINFECTIONOFPRIMARY
NORMALHUMANHEPATOCYTES
(C.GONDEAU)..............................................................................................................................................13
IDENTIFICATIONDEDEUXKINASESCELLULAIRESIMPLIQUEESALAFOISDANSL’ENTREEETLAREPLICATION
DUVHC
(M.TROTARD)..............................................................................................................................................14
ROLEDESGLYCANESDANSLESFONCTIONSDEPROTEINESD’ENVELOPPEDUVHC
(F.HELLE).....................................................................................................................................................15
HEPATITISCVIRUSENTRYISAVIABLETARGETFORPREVENTIONOFREINFECTIONINLIVER
TRANSPLANTATION
(S.FAFIKREMER).........................................................................................................................................16
CHARACTERIZATIONOFTHEMEMBRANEFUSIONPROPERTIESOFCELLCULTUREPRODUCEDHEPATITISC
VIRUSPARTICLES
(EI.PECHEUR)..............................................................................................................................................17
ANALYSEDESDETERMINANTSD’ENTREEVIRALEPORTESPARLESPROTEINESD’ENVELOPPEDUVIRUSDE
L’HEPATITEB
(Y.LEDUFF)..................................................................................................................................................18
L’ETABLISSEMENTDEL’INFECTION,LAREPLICATIONETLAPROPAGATIONDUVIRUSDEL’HEPATITEC
SERIQUE(HCVSP)DEPENDENTDEL’ETATDEPROLIFERATION/DIFFERENCIATIONDESCELLULESHEPARG
HUMAINESPROGENITRICESDUFOIE
(N.NDONGO)...............................................................................................................................................19
ETUDEULTRASTRUCTURALEETBIOCHIMIQUEDESMEMBRANESCELLULAIRESASSOCIEESAUXCOMPLEXES
DEREPLICATIONDUVHC
(P.FERRARIS)...............................................................................................................................................20
GBF1UNNOUVEAUFACTEURCELLULAIRENECESSAIREPOURLAREPLICATIONDUVIRUSDEL’HEPATITEC
(L.GOUESLAIN)............................................................................................................................................21
INVESTIGATINGTHEROLEOFTHENTERMINALBASICREGIONOFTHEHEPATITISCVIRUSCOREPROTEININ
VIRALREPLICATION
(Z.MAKOWSKA)...........................................................................................................................................22
STRUCTURESCRISTALLOGRAPHIQUESDEPOLYMERASESVIRALES:UNCONTEXTEPOURLACOMPREHENSION
DELAREPLICATIONDUVIRUSDEL’HEPATITEC
(S.BRESSANELLI)..........................................................................................................................................23
CARACTERISATIONSTRUCTURALEDESCHANGEMENTSDECONFORMATIONDELAPOLYMERASEDUVIRUS
DEL’HEPATITEC:ROLEDUCONNECTEURAL’ANCRETRANSMEMBRANAIRE
(D.HARRUS).................................................................................................................................................24
HEPATITISCVIRUSNS5APROTEINISASUBSTRATEFORTHEPEPTIDYLPROLYLCIS/TRANSISOMERASE
ACTIVITYOFCYCLOPHILINSAANDB
(X.HANOULLE).............................................................................................................................................25
ROLEDEHBXDANSL’INFECTIONPARLEVIRUSDEL’HEPATITEBDELALIGNEEHEPATOCYTAIREHEPARG
(O.HANTZ)...................................................................................................................................................26
3
TRANSACTIVATIONOFTHEHEPATITISBVIRUSCOREPROMOTERBYTHENUCLEARRECEPTORFXRΑ
(C.RAMIERE)................................................................................................................................................27
LEVIRUSDEL’HEPATITECINDUITLAFIBROSEHEPATIQUESANSINFLAMMATIONCHEZDESSOURIS
TRANSGENIQUESEXPRIMANTLATOTALITEDUCADREOUVERTDELECTUREVIRAL
(P.CHOUTEAU)............................................................................................................................................28
HEPATITISCVIRUSMODULATESHEPATOCYTEAPOPTOSISBYTARGETINGBID
(U.HIBNER)..................................................................................................................................................30
ANALYSEULTRASTRUCTURALEETQUANTITATIVEDESREGROUPEMENTSDEGOUTTELETTESLIPIDIQUES
INDUITSPARLAPROTÉINEDECOREDUVHC
(M.DEPLA)...................................................................................................................................................31
NTERMINALUBIQUITINATIONOFHEPATITISBVIRUSXPROTEIN
(S.BENHENDA).............................................................................................................................................33
LEROLEDURETROTRANSPORTDURETICULUMENDOPLASMIQUEVERSLECYTOPLASMEDELAPROTEINE
PRECOREDUVIRUSDEL’HEPATITEBHUMAINE
(M.DURIEZ).................................................................................................................................................34
HEPATITISCVIRUSNONSTRUCTURALPROTEIN2DISTURBSTHESECRETORYPATHWAYANDITSEFFECTIS
COMPENSATEDBYTHEVIRALENVELOPEPROTEINS
(N.CALLENS)................................................................................................................................................35
HEPATITISCVIRUSINFECTIONPROTEINNETWORK
(B.DECHASSEY)...........................................................................................................................................36
INHIBITIONDRASTIQUEDESECRETIONDESHEPADNAVIRUSPARUNPEPTIDEPERMEABILISANT
(F.ABDUL)....................................................................................................................................................37
CARACTERISATIOND’UNENOUVELLEMUTATIONDERESISTANCE(V36C)CHEZUNPATIENTTRAITEAVECUNE
TRITHERAPIEDETELAPREVIR,D’IFNALPHA2APEGYLEETDERIBAVIRINE
(L.BARBOTTE)..............................................................................................................................................38
EFFETANTIVIRALDUBAY414109DANSUNMODELEANIMALHUMANISEETINFECTEPARLEVHB:LASOURIS
ALBUPA/SCID
(N.BREZILLON).............................................................................................................................................40
REACTIVATIONSOUSL’ASSOCIATIONFLUTICASONERITONAVIRD'UNEINFECTIONAVHBOCCULTECHEZUN
PATIENTANTIHBS+ETCOINFECTEPARLEVIH
(A.KAY)........................................................................................................................................................41
NOUVELLESTRATEGIEANTIVIRALE:DESARNNEGATIFSCONTRELEVHC
(J.BITARD)...................................................................................................................................................43
HEPATITISCVIRUSIMPAIRSPLASMACYTOIDDENDRITICCELLASSOCIATEDPRODUCTIONOFINTERFERON
ALPHA
(I.HIRSCH)....................................................................................................................................................44
UPTAKEANDTRAFFICKINGOFCELLCULTUREDERIVEDHEPATITISCVIRUS(HCVCC)INHUMAN
PLASMACYTOIDDENDRITICCELLS
(M.LAMBOTIN)............................................................................................................................................45
REPONSENEUTRALISANTEHUMORALECONTRELEVHCLORSDELACOINFECTIONPARLEVIHETDELA
TRANSPLANTATIONHEPATIQUE
(G.MAURIN)................................................................................................................................................47
CRITICALROLEOFINTRAHEPATICCD4+CD25+FOXP3+CELLSINHCVINFECTEDPATIENTS
(E.JOUVINMARCHE)....................................................................................................................................49
ÉTUDEDEL’ENCAPSIDATIONDUGENOMEDUVHCPARMESUREDEL’INTERACTIONENTRELAPROTEINE
COREETL’ARNVIRALAUMOYEND’UNVECTEURLENTIVIRALEXVIVO
(E.PIVER).....................................................................................................................................................50
4
L’IRESDUVHCINTERAGITAVECLEMOTIFDERECONNAISSANCEMRRDELASOUSUNITEBDUFACTEUR
D’INITIATIONEIF3
(J.PERARD)..................................................................................................................................................51
ETUDESTRUCTURALEDELAPOLYMERASEMEMBRANAIREDUVIRUSDEL’HEPATITEC.PRODUCTIONET
PURIFICATIONDELAPOLYMERASEENTIERE
(C.CAILLETSAGUY)......................................................................................................................................52
DESCRIPTIOND’UNEINSERTIONV3LIKEDANSLEGENENS5ADUVIRUSDEL’HEPATITECDEGENOTYPE1B
CHEZDESPATIENTSCHRONIQUEMENTINFECTES
(O.PETSARIS)...............................................................................................................................................53
EFFETSFONCTIONNELSDESFORMESSECRETEESDUPRODUITDUGENEPRECDUVHBSURLESLYMPHOCYTES
T
(M.PURVINA)..............................................................................................................................................55
ETUDEDESREPONSESIMMUNITAIRESINDUITESPARLEVIRUSDEL’HEPATITEC:UTILISATIONDEPUCESA
PEPTIDESETAPROTEINES
(S.CORTES)..................................................................................................................................................56
EFFETINHIBITEURETCALCINEURINEINDEPENDANTDELACYCLOSPORINEASURLESCELLULEST
REGULATRICESCD4+CD25+HUMAINESINVITRO
(C.MIROUX).................................................................................................................................................58
POTENTIALISATIONDELARÉPONSEHUMORALENEUTRALISANTEDUVACCINÀADNDIRIGÉCONTRELE
DHBVPARCOADMINISTRATIONDEGÈNESCODANTPOURDESCYTOKINES
(F.SAADE)....................................................................................................................................................60
1 / 61 100%
La catégorie de ce document est-elle correcte?
Merci pour votre participation!

Faire une suggestion

Avez-vous trouvé des erreurs dans linterface ou les textes ? Ou savez-vous comment améliorer linterface utilisateur de StudyLib ? Nhésitez pas à envoyer vos suggestions. Cest très important pour nous !